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Abstract
PURPOSE: The inherent treatment resistance of glioblastoma (GBM) can involve multiple mechanisms including
checkpoint kinase (Chk1/2)–mediated increased DNA repair capability, which can attenuate the effects of genotoxic
chemotherapies and radiation. The goal of this study was to evaluate diffusion-weightedmagnetic resonance imaging
(DW-MRI) as a biomarker for Chk1/2 inhibitors in combination with radiation for enhancement of treatment efficacy in
GBM. EXPERIMENTAL DESIGN:We evaluated a specific small molecule inhibitor of Chk1/2, AZD7762, in combination
with radiation using in vitro human cell lines and in vivo using a genetically engineered GBMmouse model. DW-MRI
and T1-contrast MRI were used to follow treatment effects on intracranial tumor cellularity and growth rates, respec-
tively. RESULTS: AZD7762 inhibited clonal proliferation in a panel of GBM cell lines and increased radiosensitivity in
p53-mutated GBM cell lines to a greater extent compared to p53 wild-type cells. In vivo efficacy of AZD7762 demon-
strated a dose-dependent inhibitory effect on GBM tumor growth rate and a reduction in tumor cellularity based on
DW-MRI scans along with enhancement of radiation efficacy. CONCLUSION: DW-MRI was found to be a useful im-
aging biomarker for the detection of radiosensitization through inhibition of checkpoint kinases. Chk1/2 inhibition re-
sulted in antiproliferative activity, prevention of DNA damage–induced repair, and radiosensitization in preclinical GBM
tumormodels, both in vitro and in vivo. The effectswere found to bemaximal in p53-mutated GBMcells. These results
provide the rationale for integration of DW-MRI in clinical translation of Chk1/2 inhibition with radiation for the treat-
ment of GBM.
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Introduction
Glioblastoma (GBM) is an almost universally fatal disease. Standard
treatment of GBM typically involves surgery followed by a combina-
tion of radiation and temozolomide-based chemotherapy, which pro-
vides the best chance for long-term survival [1]. Radiation is a major
component of the standard treatment and has been shown to inde-
pendently improve survival [2]. DNA damage induced by radiation
activates the phosphoinositide (PI) 3-kinase–related family members,
ATM and ATR [3], resulting in the activation of serine/threonine
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effector checkpoint kinases, Chk1 and Chk2. Checkpoint kinase acti-
vation causes S and G2/M arrest [4–7], allowing tumor cells time to
undertake DNA repair before reentering mitosis thereby reducing the
potential for propagating potentially severe genotoxic damage that
would ultimately prove therapeutically beneficial by inducing cell death
through various processes including apoptosis, mitotic catastrophe, or
postmitotic death. In addition to regulating the cell cycle, Chk1/2
kinases can also affect processes of DNA repair, chromatin regulation,
and induction of cell death [8].
An intact G2/M arrest mechanism can also be mediated by check-
point kinases in cells, which are p53 nonfunctional. This mechanism
has also therapeutic implications as p53 mutations are known to occur
at a rate of approximately 25% to 40% and 65% to 80% in primary
and secondary GBM, respectively [9,10]. If GBM tumors are deficient
in G1 DNA damage checkpoint pathway as a result of p53 mutations
or other events, more reliance will be placed on the S and G2/M
checkpoints for DNA damage repair and survival. Therefore, inhibi-
tion of these additional checkpoints is important for effective sensiti-
zation of tumor cells to genotoxic therapies.
Stem cell research has provided evidence that CD133 (Prominin-1)–
positive GBM cells have heightened capabilities of resolving DNA dam-
agemediated by radiation. In a report by Bao et al., radiation induced an
increase in the fraction of surviving cells expressing CD133 both in vitro
and in vivo [11]. In this study, CD133+ cells were found to be more
resistant to radiation than CD133− cells through preferential activation
of theDNAdamage checkpoint pathways and an increase inDNA repair
capabilities. Furthermore, a nonspecific inhibitor of Chk1 and Chk2
kinases was found to sensitize CD133+ cells to radiation. These results
reveal that Chk1/2 pathways are highly relevant for GBM survival.
The use of quantitative imaging for evaluation of treatment response
in mouse orthotopic tumor models is useful for providing sensitive
and noninvasive metrics of treatment response. Anatomic images ob-
tained using magnetic resonance imaging scanners have been shown
to be useful for delineation of intracerebral glioma volumes in rodents
over time and to quantify the response to therapeutic intervention [12].
Moreover, diffusion-weighted magnetic resonance imaging (DW-MRI)
has been reported as an imaging biomarker for detection of the cellular
changes occurring early within a tumor following an effective cytotoxic
treatment [13]. Application of DW-MRI in this context has shown that
treatment-induced loss of tumor cellular density will result in an in-
crease in the mobility of tumor water molecules as loss in cell numbers
and associated changes in tumor tissue architecture produce a less water
diffusion–restricted environment [14]. Application of DW-MRI was
initially reported as a biomarker of therapeutic response in 9L
glioma-bearing rats treated with a chemotherapeutic agent [12,15]
and has rapidly been applied in many clinical studies and over a variety
of tumor types [16–19].
In this present study, we hypothesized that inhibition of Chk1 and
Chk2 kinases with a selective Chk1/2 inhibitor (AZD7762) would re-
sult in GBM radiosensitization. AZD7762 is a potent ATP-competitive
inhibitor with IC50s of 5 and <10 nM for Chk1 and Chk2, respectively.
AZD7762 has been shown to effectively abrogate DNA damage–
induced S and G2/M checkpoints [20]. We also hypothesized that these
effects would predominate in p53-mutated cells. In this report, we
show that AZD7762 has in vitro and in vivo efficacy alone and poten-
tiates the effects of radiation in GBM. These findings provide a strong
rationale for evaluating the use of checkpoint kinase inhibitors in
combination with current GBM treatment, optimally directed at
p53-mutated tumors.
Materials and Methods
Antibodies, Chemicals, and Cell Culture
Anti-cdc25a antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-Chk1, Chk2, phospho-Chk1 (S345), phospho-
Chk1 (S296), phospho-H2AX (S139), phospho-p53 (S15), and
GAPDH antibodies were purchased from Cell Signaling Technology
(Danvers, MA). Ki67 antibody was purchased from Dako (Carpinteria,
CA). AZD7762 was purchased from AxonMedChem (Groningen, The
Netherlands). The structure for AZD7762 is shown in Figure 1A. For
in vitro studies, AZD7762 was dissolved in DMSO. For in vivo studies,
AZD7762 was dissolved in 11.3% 2-hydroxypropyl-β-cylodextrin
(Sigma-Aldrich, St Louis, MO) in 0.9% sterile saline, vortexed, stored
at 4°C, and used within 14 days. Human U251 cells were grown in
Dulbecco’s modified Eagle’s medium with 10% FBS, D4MG cells in
RPMI 1640 with 10% FBS, U87 cells in Dulbecco’s modified Eagle’s
medium with 10% FBS, and SKMG-3 cells in alphaMEM with 10%
fetal calf serum and 10mMHepes. Cells were grown in a 37°C incubator
with 5% CO2.
Immunoblot Analysis
Cell lysates were prepared immediately in RIPA lysis buffer [1%
NP-40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 0.25% Na-
deoxycholate, 1 mM EDTA] supplemented with 1× protease inhibi-
tor (cOmplete; Roche Applied Science, Indianapolis, IN) and phos-
phatase inhibitors (PhosSTOP; Roche Applied Science). Protein
concentration was determined with a DC Protein Assay Kit (BioRad,
Hercules, CA). Proteins were resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to nitrocellulose
Figure 1. AZD7762 inhibits Chk1 and Chk2 activity in U251 cells.
U251 cells were pretreated for 1 hour with DMSO or AZD7762
(100 nM) and treated with and without radiation (6 Gy). Three
hours later, cells were lysed and extracts were immunoblotted
for cdc25A, phospho-Chk1 (S345 and S296), Chk1, Chk2, phospho-
H2AX (S139), and phospho-p53 (S15). GAPDH was shown as equal
loading control.
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membranes. Primary antibodies were allowed to bind for 2 hours at
room temperature and used at a dilution of 1:500 to 1:2000, except for
GAPDH that was used at 1:10,000. After washing in TBS-Tween,
membranes were incubated with HRP-conjugated secondary anti-
bodies diluted 1:10,000 for 1 hour. Membranes were washed with
TBS-Tween and incubated for 1 minute with enhanced chemilu-
minescence reagent (Amersham Pharmacia, Uppsala, Sweden) before
film exposure.
Flow Cytometry
Cells were plated in six-well dishes, pretreated for 1 hour with
DMSO or AZD7762, and treated with or without radiation. At
24 hours following radiation exposure, cells were harvested with tryp-
sin, washed with medium, spun down, and resuspended in 1 ml of
phosphate-buffered saline (PBS). Cells were immediately fixed for
30 minutes with 9 ml of ice-cold 80% ethanol added slowly with mix-
ing. Cells were washed twice with PBS and resuspended in 1 ml of PBS
containing 10 μg/ml propidium iodide and 0.25 mg/ml RNase A. Cells
were incubated for 30 minutes and stored in the dark before analysis.
Cells were then transferred to 5-ml polystyrene round bottom tubes
through cell strainer lids and analyzed on a FACSCalibur (BD Bio-
sciences, San Jose, CA). Data were fit using ModFit LT (Verity Soft-
ware House, Topsham, ME).
Clonogenic Survival Assays
Cells were trypsinized to generate single-cell suspensions and cells
were seeded into six-well or 60-mm tissue culture plates (in triplicate).
Cells were incubated with DMSO or AZD7762 for 1 hour before
irradiation and kept in DMSO or AZD7762 for a total of 24 hours
after radiation before changing the medium. For experiments without
radiation, cells were incubated with DMSO or AZD7762 for 24 hours
before changing the medium. At 10 to 14 days after seeding, colonies
were stained with 0.5% crystal violet, and the numbers of colonies con-
taining at least 50 cells were determined. Plating efficiency, survival
fractions, and dose enhancement ratios were calculated according to
previously described methods [21]. For each condition, six wells were
plated in replicate for experiments performed in six-well plates and in
triplicate for experiments performed in 60-mm culture plates. Experi-
ments were repeated multiple, independent times.
In Vivo Tumor Studies
We used a well-validated genetically engineered mouse model of
GBM [INK4a/ARF(−/−) PTEN(loxP/loxP)/Ntv-a RCAS/PDGF(+)/
Cre(+)], which lacks the tumor suppressors INK4A/ARF (p16 and
p19ARF) and PTEN, with overexpression of PDGF to drive formation
of GBM [22,23]. In this model, PTEN is deleted in nestin-expressing
cells in an INK4A/ARF-deficient mouse background, and PDGF is
overexpressed using RCAS-tva technology. The PDGF-driven model
has been shown to exhibit pathologic features similar to the human
disease counterpart and represents a proneural model. The lack of
p19ARF in this model renders tumor cells functionally p53 deficient
since ARF normally inhibits the p53 inhibitor Mdm2. More specif-
ically, ARF functions as a tumor suppressor by forming complexes with
Mdm2, an E3 ubiquitin ligase that serves as a negative regulator of p53.
Upon DNA damage, phosphorylation of Mdm2 allows stabilization
and activation of p53 to promote cell cycle arrest and DNA repair.
Thus, a vital role of ARF is to activate p53-dependent cell cycle arrest
and apoptosis. Because ARF is deleted in this model, Mdm2 activity
is high, resulting in p53 dysregulation and relative functional inactiva-
tion of p53 in response to DNA damage.
All animal procedures described herein were approved by the Uni-
versity of Michigan Committee for Use and Care of Animals (Protocol
No. 09583). The generation of RCAS–PDGF-B and RCAS-Cre–
transfected DF1 cells has been previously described [22]. Briefly, 8 ×
104 cells were implanted under stereotactic guidance using a 30-gauge
needle into the right frontal cortex of transgenic mice at a depth of
3 mm. After implantation, tumor volumes were monitored and calcu-
lated using contrast-enhanced T1-weighted MR images. Once tumor
volumes reached 20 to 40 μl on pretreatment MRI, animals were ran-
domized to a treatment arm. Animals were monitored carefully and
sacrificed at the end of the treatment schedule for histologic analysis.
MRI Evaluation of Tumor Treatment Responses
MRI was performed using a 9.4-T, 16-cm horizontal bore (Agilent
Technologies, Inc, Santa Clara, CA) Direct Drive System with a mouse
head quadrature volume coil or mouse surface receive coil (m2m
Imaging, Corp, Cleveland, OH) actively decoupled to a whole-body
volume transmit coil (Rapid MR International, LLC, Columbus,
OH). Throughout the MRI experiments, animals were anesthetized
with 1% to 2% isoflurane/air mixture, and body temperature was
maintained using a heated air system (Air-Therm Heater; World Pre-
cision Instruments, Sarasota, FL). MR images were acquired before
treatment initiation, then every other day until the animals were sacri-
ficed or became moribund. MR imaging sequences were used in this
study to measure tumor volumes over time [12] as well as for quan-
tification of tumor apparent diffusion coefficient (ADC) values [22].
Delineation of tumor from healthy brain tissue was accomplished using
contrast-enhanced T1-weighted spin-echo images with the following
acquisition parameters: repetition time/echo time = 510/15 ms, field
of view = 20 × 20 mm2, matrix size = 128 × 128, slice thickness =
0.5 mm, 25 slices, and two averages. Total acquisition time was 2 min-
utes and 12 seconds. An intraperitoneal injection of 50 μl of 0.5 M
gadolinium-DTPA (Magnevist; Bayer Healthcare Pharmaceuticals,
Wayne, NJ) 5 minutes before image data acquisition was used to
provide for contrast enhancement of the tumor.
Tumor ADC maps were derived using a DW spin-echo sequence,
equipped with a navigator echo for motion correction and gradient
waveforms sensitive to isotropic diffusion, with the following param-
eters: repetition time/echo time = 4000/37 ms, field of view = 20 ×
20 mm2, matrix size = 128 × 64, slice thickness = 0.5 mm, 25 slices,
one average, diffusion time = 40 ms, gradient pulse width = 10 ms, and
b values (diffusion weighting) = 120 and 1200 s/mm2. Total acquisi-
tion time was approximately 8.5 minutes. Diffusion scans were used to
follow early changes in tumor cellular density during the initial 7 days
posttreatment initiation.
For longitudinal quantification of tumor volumes, volumes of inter-
est were contoured along the enhancing tumor rim using the contrast-
enhanced T1-weighted images. Tumor volumes were used to follow
treatment response for the individual treatments. The tumor regions
were also used to derive whole-tumor means of ADC values over
time for individual animals. ADC maps were calculated from the two
diffusion weightings (b values) using the following equation:
ADC =
ln S1S2
 
ðb2 − b1Þ ;
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where S1 and S2 are the signal intensities at b values b1 and b2, respec-
tively, and ADC is the ADC obtained using b1 and b2. Voxels that
exhibited insufficient signal, which was defined as <10× noise, in the
low b value image (b = 120 s/mm2) were excluded from the analysis.
Image reconstruction and digital image analysis were done using soft-
ware algorithms developed in Matlab (The MathWorks, Natick, MA).
Early response in mean ADC values was assessed by the area under
the curve (AUC) of the mean tumor ADC from baseline to day 5
posttreatment initiation. The AUC from 0 to day 5 was determined
by calculating the AUC at incremental time points using the trape-
zoidal rule and summing over all incremental AUC values, i.e.,
AUC ¼
X
i
t  ti1ð Þ  ðAUCi1 þ AUCiÞ=2
Experimental Radiation
Radiation was performed at 320 kVp and 10 mA using an IC-320
orthovoltage irradiator (Kimtron Medical, Bantam, CT). For in vitro
experiments, a 20 × 24 cm cone was used at a source-to-surface dis-
tance of 50 cm at a dose rate of ∼434 cGy/min. For animal irra-
diation, a 6 × 8 cm cone was used at a source-to-surface distance
of 40 cm at a dose rate of ∼138 cGy/min. Dosimetry was carried
out using an ionization chamber connected to an electrometer system
that was directly traceable to a National Institute of Standards and
Technology calibration. Mice were anesthetized with a 1% to 2%
isoflurane/air mixture and placed in restraining device, and whole
brain was irradiated while the rest of the body was shielded using
a custom-cut lead secondary collimator. In vivo administration of
AZD7762 (15 mg/kg) along with radiation therapy (RT; 1 Gy) was given
concurrently daily for 5 days a week over a 2-week period.
Immunohistochemistry
At the conclusion of the experiments, intracranial tumors were har-
vested and fixed in 10% neutral-buffered formalin for at least 48 hours
(n = 4 per group). Tumors were sectioned and paraffin embedded, and
5-μm sections were cut onto slides. Paraffin was removed in xylene,
and slides were rehydrated through gradually decreasing alcohol con-
centrations 2 min/step before ending in tap water (100% ethanol,
95% ethanol, 70% ethanol, water). Antigen retrieval was performed
by microwaving slides for 10 minutes in pH 6.0 citrate buffer, followed
by a 10-minute cooling period and a 10-minute running water wash.
Immunoperoxidase staining was performed on a Dako AutoStainer at
room temperature by applying peroxidase block (5 minutes), buffer
rinse, primary antibody (30 minutes), buffer rinse, secondary antibody
(EnVision + anti-rabbit; 30 minutes), buffer rinse, DAB (5 minutes),
buffer rinse, followed by hematoxylin counterstain (2 seconds) and
water rinse. Slides were then dehydrated through gradually decreasing
alcohol concentrations (70% ethanol, 95% ethanol, 100% ethanol,
2 minutes each), three xylene washes (2 minutes each), and followed
by placement of a coverslip. Images were captured on an Olympus
BX-50 microscope (original magnification, ×4–40).
Data Analysis
Data were presented as mean ± SEM for clonogenic survival and
tumor growth experiments. The group comparisons of the percent
change in tumor volume were performed at individual time points.
Statistical comparisons were made between the control and experi-
mental conditions using the unpaired two-tailed Student’s t test with
significance assessed at P values < .05.
Results
Effects of AZD7762 on Chk1 and Chk2 Activation and
Radiation-Induced G2/M Arrest
The ability of AZD7762 to inhibit Chk1 and Chk2 activity was ini-
tially evaluated in vitro using U251 GBM cells. Chk1 is involved in
regulation of levels of cdc25A, a phosphatase that controls progres-
sion through the cell cycle [8]. Activation of cdc25A allows efficient ac-
tivation of CDK2, allowing cell cycle progression through various
checkpoints. Upon Chk1 activation after DNA damage, Chk1 phos-
phorylates cdc25A resulting in ubiquitin-mediated cdc25A degradation,
allowing cell cycle arrest. As shown in Figure 1, AZD7762 treatment
stabilized cdc25A, resulting in an increase in cdc25A levels in U251
cells. In addition, AZD7762 treatment increased phospho-Chk1
(S345), which has been observed previously and appears to be related
to amplification of the ATM/ATR-mediated DNA damage response
[23]. As expected, radiation alone activated Chk1 and Chk2 as deter-
mined by increased levels of phospho-Chk1 (S345 and S296) and
decreased gel mobility of Chk2 (indicating increased phospho-Chk2),
as well as resulting in increased levels of phospho-p53 (S15) and
phospho-gammaH2AX (S139), both markers of DNA damage induced
by radiation. Furthermore, the ability to undergo autophosphorylation
(S296) was inhibited by AZD77262 both in the presence and absence
of radiation, which has been shown previously [23]. Lastly, AZD7762
also abrogated Chk2 activation after radiation, as seen by the loss of the
decreased gel mobility of Chk2.
To confirm the effects of AZD7762 on cell cycle progression, we
performed flow cytometry on U251 cells. Cell cycle analysis was per-
formed following treatment of U251 cells cultured at the exponential
phase of growth with combinations of DMSO, AZD7762, and RT
(6 Gy) to determine G1, S, and G2/M phase fractions at 24 hours
after radiation. For these studies, cells were pretreated for 1 hour with
DMSO or AZD7762 before radiation. Twenty-four hours after radia-
tion, cells were fixed, stained with propidium iodide, and analyzed by
flow cytometry. As shown in Table 1, radiation induced a G2/M arrest
as expected, resulting from activation of checkpoint kinases and DNA
damage repair pathways. Almost no cells were noted in S phase. In the
presence of AZD7762, however, there was significant loss of the pro-
portion of cells in G2/M, indicating that many cells were allowed to
prematurely reenter the cell cycle, as noted by increased populations
of G1 and S phase cells.
p53-dependent Effect of AZD7762 on Cell Proliferation
and Radiosensitization
A panel of human GBM cell lines consisting of U251, D54MG,
U87, and SKMG3 cells was used to evaluate the effects of AZD7762
on proliferation and survival. Clonogenic proliferation assays were
Table 1. Treatment Effects on U251 GBM Cell Cycle.
U251 24 Hours
G1 (%) S (%) G2/M (%)
DMSO 40.0 33.5 26.4
AZD7762 48.0 33.2 18.8
DMSO + RT 12.4 0.0 87.8
AZD7762 + RT 32.8 42.7 24.6
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performed by plating equal cell numbers at very low density, incubat-
ing with varying concentrations of AZD7762 for 24 hours, and then
allowing cells to form colonies (defined as >50 cells) over the next 10 to
14 days. As shown in Figure 2A, all cell lines were sensitive to increas-
ing doses of AZD7762, albeit with differential sensitivity. Interestingly,
the two p53 mutant cell lines, U251 and SKMG3, had the greatest
degree of sensitivity to AZD7762. In fact, SKMG3 cells showed dra-
matic sensitivity even at concentrations as low as 0.1 μM.However, the
two p53 wild-type cell lines showed the most resistance to AZD7762.
Next, radiation clonogenic assays were carried out to test the radio-
sensitivity of multiple GBM cell lines. Cells were pretreated with
AZD7762 for 1 hour followed by increasing doses of radiation, followed
by the continued presence of AZD7762 for 24 hours. Of the p53 wild-
type cell lines D54MG and U87, no radiosensitization was observed
with AZD7762 (data not shown). However, both p53 mutant cell lines
U251 and SKMG3 showed significant radiosensitization after treatment
with AZD7762, with dose enhancement ratios of 1.25 and 1.44, respec-
tively (Figure 2B). These data are consistent with the overall hypothesis
that Chk1/2 inhibitors specifically enhance the cytotoxicity of DNA-
damaging agents in checkpoint-defective p53 mutant tumors.
Concurrent Treatment with AZD7762 and Radiation
Improves Therapeutic Response In Vivo
We initially performed a dose response experiment to test the effect
of increasing concentrations of AZD7762 on the tumor growth in this
GBMmousemodel.We performedMRI screening of mice as previously
described [22]. Once intracranial tumors of 20 to 40 μl were identified
by screeningMRI, mice were randomized to control (vehicle) and 5, 15,
Figure 2. AZD7762 inhibits proliferation and radiosensitizes a panel of GBM cells in a p53-dependent manner. (A) Clonogenic prolifera-
tion assays were performed on a panel of GBM cell lines, including U251, D54MG, U87, and SKMG3 cells. Cells were treated with a
range of concentrations of AZD7762 for 24 hours and allowed to form colonies after 10 to 14 days. Cells most sensitive to treatment
with AZD7762 were the two p53 mutant cell lines, U251 and SKMG3. (B) Clonogenic survival assays were performed by pretreating cells
with DMSO or AZD7762 (200 nM) for 1 hour before increasing doses of radiation, then changing the medium 24 hours later and allowing
the cell lines to form colonies over 10 to 14 days. AZD7762 treatment resulted in substantial radiosensitization in p53 mutant cell lines
U251 and SKMG3 but not p53 wild-type cell lines U87 and D54MG. Asterisks indicate P value < .05 compared to DMSO-treated cells.
Error bars represent SEM.
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or 25 mg/kg AZD7762 delivered by intraperitoneal injection daily for
2 weeks at 5 days per week. As shown in Figure 3, the 5 mg/kg dose had
no significant effect on tumor growth compared with vehicle-treated
mice. However, increasing doses of 15 and 25 mg/kg demonstrated a
dose-dependent effect of AZD7762 on GBM growth inhibition.
The efficacy of AZD7762 in combination with radiation was
evaluated for improvement in tumor control using the PDGF-driven
genetically engineered GBM model. Mice were screened until they de-
veloped tumors ranging in size from 20 to 40 μl and then randomized
to 1) vehicle control, 2) AZD7762, 3) radiation (RT), or 4) AZD7762
concurrent with RT (with AZD7762 administered 1 to 2 hours before
radiation). Representative coronal T1 Gd-contrast MR images from
each of the treatment arms over 15 days are shown in Figure 4. As
shown in Figure 4 and quantified in Figure 4B, vehicle-treated tumors
grew at a rapid pace increasing about 800% in tumor volume over a
7-day time period during the course of the study. Treatment with
radiation or AZD7762 as single therapies significantly inhibited the
overall tumor growth rate over control tumors. However, as shown
in Figure 4B, a larger therapeutic benefit based on larger tumor growth
rate inhibition from AZD7767 administration over that of RT alone
was observed during the end of the second week of treatment. All
tumor volumes were significantly different (P < .05) from control
tumor volumes beginning at day 3 posttreatment initiation. The com-
bined therapy group was also significantly different (P < .05) from the
other three groups beginning at day 3 posttreatment initiation. Tumors
treated with the combination of AZD7762 and radiation were found
to have the most significant therapeutic response. These mice survived
the longest, with 22% surviving by the end of the predefined end of
the study (23–25 days, mouse with significant neurologic signs, or
tumor >150 μl) compared to 0% for all other groups. Importantly,
mice were weighed twice weekly and monitored closely during therapy
administration and had no significant toxicity with only a maximum
7% decline in body weight in any of the treated groups. Once tumors
grew to a large size, all mice began to lose weight likely as a function
of decreased neurocognitive ability.
DW-MRI Reveals AZD7762-Mediated Loss of GBM
Cellular Density
The AUCs of mean tumor ADC values over the first 5 days of frac-
tionated dose treatment cycle for each treatment group are presented
in Figure 5. Control animals were found to have significantly smaller
AUC values over this time frame compared to the treatment groups.
In contrast, single-agent therapy using RT or AZD7762 both had in-
creased ADC tumor values resulting in a significantly high AUC value
over control animals during the first cycle of treatment. Furthermore,
while efficacy for both AZD7762 and RT was observed, the combina-
tion of AZD7762 and RT was the only treatment group found to have
gained control of tumor growth over the 2-week, two-cycle treatment
time period (Figure 4B). Following one full cycle of treatment with
chemoradiation, a significantly higher increase in tumor ADC values
was found in the combined treatment group compared to the single-
agent treatment groups when the AUCs of the mean ADC values were
compared (Figure 5). Thus, the combination therapy group not only
had the largest increase in tumor ADC values (Figure 5) but was also
found to have the correspondingly most efficacious treatment benefit
(Figure 4B). It was also noteworthy that following the first treatment
cycle from days 0 to 4, tumor ADC values all began to decrease from
days 5 to 7 (data not shown). During this time frame, animals were not
treated and the drop in diffusion values indicates a probable repopula-
tion of tumor cells occurring during that time interval as increased
density of tumor cells would result in a more impeded water diffusion
environment within the tumor mass [24]. Tumor ADC maps from
representative animals are also shown for each of the five groups at
day 5 posttreatment initiation. Tumors treated with single agents ex-
hibited a modest shift in increased diffusion values, whereas the largest
effect was found in the combination therapy (RT + AZD7762).
Immunohistochemical Evaluation of In Vivo GBM
Treatment Effects
To study the effects of AZD7762 on tumor cell proliferation, intra-
cranial tumors were harvested several hours at the conclusion of the
overall 2-week study and subjected to immunohistochemistry. Tumors
displayed findings similar to human GBM, including nuclear atypia,
mitotic figures, areas of necrosis, and vascular/endothelial proliferation
as depicted in Figure 6A. As shown in Figure 6B, control tumors dis-
played high Ki67 staining indices, consistent with rapid GBM tumor
proliferation. Treatment with RT resulted in mild decreases in Ki67
staining patterns, but AZD7762 markedly decreased the proliferative
indices in tumors, consistent with antitumor activity in this model.
This effect was similarly apparent in the combination AZD7762 and
radiation-treated tumors.
Discussion
The development of targeted therapies requires an early response bio-
marker, and ADC can be used for this purpose. DW-MRI has been
shown to be a useful noninvasive biomarker for evaluating early effects
of anticancer therapies [15,25,26] and applicable to a wide variety of
tumor models [27–31]. The applicability of DW-MRI relies in the
sensitivity of the method to treatment-induced alterations in micro-
scopic tissue structure and physiology, which are reflected in signifi-
cant changes to water movement within the tumor microenvironment
[32,33]. Recent studies have also revealed the clinical translatability of
Figure 3. In vivo dose response of AZD7762.Micewere randomized
to 1) control (vehicle; n= 7), 2) 5mg/kg AZD7762 (n= 4), 3) 15mg/kg
AZD7762 (n=10), or 4) 25mg/kg AZD7762 (n=6). Therewas a dose-
dependent effect with AZD7762with increasing concentration resulting
in higher tumor growth inhibition.
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DW-MRI for early treatment response assessment in patients with pri-
mary brain tumors [26,34,35]. In the present study, DW-MRI provided
the ability to dynamically follow the response of single or combination
treatments by serially observing changes in tumor ADC values. Thus,
integration of DW-MRI into a clinical GBM trial to follow treatment
response would be anticipated to be valuable for assessing overall effects
of AZD7762 in GBM patients and could provide an opportunity to
optimize initial regimens.
Outcomes in GBM are poor largely related to treatment resistance to
radiation and genotoxic chemotherapy such as temozolomide, in part
due to heightened DNA damage response repair mechanisms in GBM
cells [11,36]. Classic models are that most cancers are impaired in one
or more DNA damage response pathways, allowing them to proliferate
more rapidly than most normal cells. However, there is accumulating
evidence that treatment-refractory tumors have evolved enhanced DNA
repair capabilities to circumvent death. In one study, Bartkova et al.
Figure 4. MR images and treatment response. (A) MRI data consist of anatomic contrast-enhancing coronal T1-weighted images for rep-
resentative animals from each of the treatment groups from pretreatment (day 0) to days 5, 7, and 15. Day 15 is not shown for the control
animal due to the rapid tumor growth for untreated animals. (B) MRI-determined intracerebral tumor volumes over time for each treatment
group. Treatments occurred for 10 days total, 5 days/week. MRI was performed every other day during treatment and thereafter to deter-
mine tumor volume until end of study period for 1) control (n = 7), 2) 15 mg/kg AZD7762 (n = 10), 3) RT (n = 10), or 4) AZD7762 + RT
(n = 12). Error bars represent SEM. All tumor volumes were significantly different (P < .05) from control tumor volumes beginning at
day 3 posttreatment initiation. The combined therapy group was also significantly different (P< .05) from the other three groups beginning
at day 3 posttreatment initiation.
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found increased levels of activated ATM,Chk2, and p53 in early tumor-
igenesis, suggesting heightened DNA repair mechanisms to counteract
the genomic andmitotic stress encountered by tumors during rapid pro-
liferation [37]. In GBM, this was nicely demonstrated in a report by
Bao et al., which showed that glioma stem cells display an overexuberant
DNA damage repair pathway and are resistant to radiation [11]. Further-
more, they also demonstrated that this effect was partly dependent on
checkpoint kinases. Therefore, we hypothesized that targeting Chk1/2
kinases could serve to enhance the effects of radiation or genotoxic
chemotherapy in glioma cells.
Figure 5. DW-MRI during the first 5 days of posttreatment initiation. The mean DW-MRI–derived ADC values for each of the treatment
groups were obtained by AUC analysis of tumor ADC values from pretreatment to day 5 posttreatment initiation. Error bars represent
SEM. RT and AZD7762 treatment groups were significantly different from the control group and the RT + AZD7762 group was significantly
different from the ionizing radiation (IR; P< .001), AZD7767 (P< .02), and control (P<.001) groups at day 5. Color ADC overlay maps from
representative tumors treated for 5 days are shown for each of the individual groups.
Figure 6. Histologic effects of AZD7762. (A) H&E-stained sections of control (vehicle-treated) tumors isolated at the end of the treatment
schedule. The dashed line in the top panel represents that border between normal brain tissue (B) and the tumor. Tumors display typical
hallmarks of human GBM, including areas of necrosis (N), endothelial proliferation (E), mitoses (M), and atypia (A). Top panel represents
images taken at ×10 magnification, while the bottom panel is ×40. (B) Ki67 staining performed on tumor sections isolated from day 2
for the different treatment groups from Figure 4B (n = 4 per treatment group). Representative images are shown. Control (vehicle)
tumors demonstrated high levels of Ki67-positive cells. RT induced modest decreases in Ki67 staining. However, treatment with
AZD7762 resulted in marked decreases in the proportion of Ki67-positive cells. Sold bars are provided for magnification.
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We now have a much better understanding of the genomic land-
scape of GBM [9,10,38]. It is well established that p53 mutations
are common in primary and secondary GBM, occurring with a fre-
quency of about 25% to 40% and 65% to 80%, respectively. Among
its many functions, the tumor suppressor p53 is responsible for ac-
tivating cell cycle arrest particularly at the G1 checkpoint, to allow
time for DNA repair in response to radiation or DNA-damaging
chemotherapy. In p53-mutated tumors, cells rely more heavily on S
and G2 phase checkpoints to repair DNA damage after treatment.
Thus, inactivation of the S and G2 checkpoints represents an applica-
tion of the synthetic lethality concept to enhance tumor cell kill.
Among many cell cycle regulators, checkpoint kinases 1 and 2
(Chk1 and Chk2) are critical for monitoring progression through S
and G2 phases [4–7]. These kinases act downstream of ATM and
ATR kinases and possess important roles in cell cycle control, tissue
development, and DNA damage repair. Upon activation, Chk1 be-
comes phosphorylated at Ser317 and Ser345 and undergoes auto-
phosphorylation at Ser296. These processes allow Chk1 to localize to
the nucleus and exert its cell cycle regulatory functions. Activated
Chk1 kinase phosphorylates cdc25A, targeting it for degradation, and
phosphorylates cdc25C to invoke cell cycle arrest through blocking
of cdc2. Chk2 is activated by ATM/ATR through phosphorylation
of multiple sites by ATM/ATR kinases, regulates cdc25C phospha-
tase activity, and interacts with BRCA1 to restore survival after DNA
damage [39,40].
AZD7762 is a potent and highly selective inhibitor of Chk1/2
kinases, which blocks cdc25A degradation, inactivates cdc25C, and
allows cell cycle progression [20]. Thus, inhibiting S and G2 phase
checkpoints allows continued cell cycle progression and inability of
cells to efficiently repair DNA damage, ultimately resulting in their
death. We demonstrate here that treatment with AZD7762 results
in reductions in GBM growth rates, clonal proliferation, and survival
after radiation both in vitro and in vivo. We also demonstrate that
these effects are maximal in p53-mutated cells.
Other groups have also shown the relative benefits of incorporating
Chk1/2 inhibitors in combination with genotoxic compounds (e.g.,
gemcitabine and irinotecan) and/or radiation in other disease models,
such as pancreatic, colon, prostate, and lung cancers [21,41]. Effective
radiosensitization by checkpoint kinase inhibition also likely requires
active movement through the cell cycle as has been demonstrated pre-
viously [41]. These findings also confirm the conclusions derived using
pancreatic cancer–derived cell lines in that p53 mutant status resulted
in the greatest degree of radiosensitization although p53 wild-type cells
were also significantly sensitized compared to normal cells [41,42].
Furthermore, there is evidence that the presence of phosphorylated
Chk1 (S345) may serve as a biomarker of AZD7762 response, with
pChk1 (S345) levels increasing after treatment with AZD7762 [23].
Our findings corroborate this concept, with slight increased levels of
pChk1 (S345) after AZD7762 treatment noted on immunoblots of
U251 cells (Figure 1B).
As the standard treatment for GBM consists of surgery followed by
a regimen of concurrent radiation and temozolomide, one must con-
sider whether Chk1/2 inhibition can be incorporated into current stan-
dard of care. In GBMs, temozolomide appears to exert a G2/M arrest
in a p53-independent manner. In p53-proficient cells, prolonged treat-
ment results in senescence, while p53-null cell treatment leads to
mitotic catastrophe. Therefore, p53-deficient glioma cells appear more
sensitive to the effects of temozolomide [43]. Since G2/M arrest may
protect cells from temozolomide-induced cytotoxicity, by allowing
reversal of the cytotoxic effects of the drug for entry into mitosis and
death by mitotic catastrophe, reversal of the G2/M arrest may promote
more sensitivity to temozolomide. In addition, it has been previously
shown that temozolomide induces G2/M arrest by activating Chk1 and
Chk2, resulting in subsequent cdc25C and cdc2 phosphorylation
[44,45]. Treatment with the Chk1 kinase inhibitor, UCN-01, poten-
tiated temozolomide-mediated cytotoxicity by allowing cells to bypass
G2/M arrest and die from resulting mitotic catastrophe. This occurred
in both p53-proficient and p53-deficient GBM cells [45]. Taken
together, there is significant evidence that combining temozolomide
and Chk1/2 is a rational approach for treating GBM.
In summary, we have demonstrated that radiation activates check-
point kinases in GBM and that targeting Chk1/2 kinases results in
substantial inhibition of GBM cell growth, while enhancing radiation
efficacy in a panel of GBM cell lines as well as a transgenic GBM
mouse model. The therapeutic effectiveness was enhanced in p53-
mutated cells confirming our hypothesis that loss of p53 function
enforces S and G2 checkpoint dependency. Selectively targeting p53-
deficient tumors with checkpoint kinase inhibition in combination with
radiation thus would provide a greater therapeutic index that would
serve to limit toxicity to normal tissues. Additionally, DW-MRI can
play an important role in the preclinical development of novel thera-
peutic strategies directed against GBM. Our results provide rationale
for exploring a regimen combining checkpoint kinase inhibition with
radiation, optimally in p53-mutated GBM and for the integration of
DW-MRI into the clinical trial protocol.
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